Search results
Results from the WOW.Com Content Network
The recommended use is the two-letter country code followed by the patent document number and then the kind code, e.g., "US 7,654,321 B1" for U.S. Patent No. 7,654,321 where there was no previously-published patent application publication, and "US 2003/1234567 A1" for U.S. Patent Application Publication No. 2003/1234567, published in 2003. [1]
The information submitted in an IDS typically includes other issued patents, published patent applications, scientific journal articles, books, magazine articles, or any other published material that is relevant to the invention disclosed in the applicant's own patent application, irrespective of the country or language in which the published material was made.
In the United States, to have patent claims "rejected" in a patent application means that the subject matter as claimed is considered by the patent examiner to be unpatentable. [56] A final Office action based on rejection of claims is subject to review by the Board of Patent Appeals and Interferences (BPAI). cf Objections, supra.
This is a list of special types of claims that may be found in a patent or patent application.For explanations about independent and dependent claims and about the different categories of claims, i.e. product or apparatus claims (claims referring to a physical entity), and process, method or use claims (claims referring to an activity), see Claim (patent), section "Basic types and categories".
A medical patent may refer to a biological patent (see also gene patent) a chemical or pharmaceutical patent; a patent on a medical device; Second medical indication ...
number (required) is a patent number, without leading "US" letters, but with leading "D" letter if patent number contains it, and is required. issue-date (optional) is the date of issuing (granting). inventor (optional) is a name of inventor; it can be a wiki-link, of course. title (optional) is the title of the patent.
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...
No patent system today is a purely either central or peripheral, but the system used in Germany and most of the other countries of continental Europe is considered more central than the system currently used in the United Kingdom, the United States, and especially Japan, which are more peripheral. [7]